Open Payments

U OF U HOSPITALS & CLINICS

Type
Teaching hospital
Where
Salt Lake City, UT
Medicare CCN
460009
Received
$37,145,780 in 3,756 records, 2025 ($3,697,329 general, $33,448,451 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment239$3,697,329
2025Research payment3,517$33,448,451

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP23$3,303,7532025
Merck Sharp & Dohme LLC37$3,263,8322025
Janssen Research & Development, LLC197$2,315,9472025
ABBVIE INC.224$1,870,7572025
Novavax Inc5$1,820,4912025
E.R. Squibb & Sons, L.L.C.25$1,564,1842025
PFIZER INC.172$1,561,3002025
Regeneron Pharmaceuticals, Inc.73$1,365,9562025
Takeda Pharmaceuticals U.S.A., Inc.110$887,5252025
BeOne Medicines Ltd.37$771,4622025
UCB SA11$722,6042025
Sumitomo Pharma America, Inc.840$710,0272025
Incyte Corporation162$699,3502025
AstraZeneca UK Limited4$651,7382025
Boston Scientific Corporation22$615,0772025
Amicus Therapeutics, Inc.13$606,0002025
Alexion Pharmaceuticals, Inc.12$589,0262025
BeiGene, Ltd.18$529,3192025
Boehringer Ingelheim Pharmaceuticals, Inc.42$523,8222025
Eli Lilly and Company16$513,9002025
Daiichi Sankyo Inc.351$466,2472025
PharmaEssentia USA Corporation33$453,6242025
Abbott Laboratories81$399,9612025
LEO Pharma Inc.5$398,0632025
Janssen Scientific Affairs, LLC5$359,7292025
Blueprint Medicines Corporation36$338,4172025
Ionis Pharmaceuticals, Inc.15$337,4422025
SANOFI US SERVICES INC.44$314,3472025
United Therapeutics Corporation49$310,0562025
VERTEX PHARMACEUTICALS INCORPORATED12$275,1382025
Lilly USA, LLC1$268,3982025
COLOPLAST CORP2$249,5002025
PTC Therapeutics, Inc.12$239,8362025
Alnylam Pharmaceuticals Inc.8$235,2432025
Biogen, Inc.8$219,4342025
Novo Nordisk AS3$216,2622025
ACADIA Pharmaceuticals Inc8$213,0352025
Medtronic, Inc.31$207,9742025
Ipsen Biopharmaceuticals, Inc1$207,7502025
Epizyme, Inc.88$203,9682025
Olympus Corporation of the Americas3$200,8302025
Genentech, Inc.11$198,0642025
Astellas US Technologies2$196,6302025
ADC THERAPEUTICS AMERICA, INC.15$191,3092025
SPR Therapeutics, Inc11$182,7312025
ModernaTX, Inc.33$171,4222025
Edwards Lifesciences Corporation18$171,2782025
JAZZ PHARMACEUTICALS INC.24$162,7812025
National Marrow Donor Program19$158,6232025
Syndax Pharmaceuticals, Inc.4$157,9512025

By nature of payment

NatureRecordsAmount
Research payment3,517$33,448,451
Grant60$1,668,809
Compensation for services other than consulting, including serving as faculty or as a speaker at a v34$771,352
Space rental or facility fees (teaching hospital only)92$538,104
Consulting Fee9$429,855
Royalty or License5$128,925
Education20$93,706
Long term medical supply or device loan3$36,709
Debt forgiveness10$13,745
Gift3$9,500
Charitable Contribution3$6,620

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$323,216Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2025
2025-12-31Merck Sharp & Dohme LLC$296,450Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary 2025
2025-12-31Merck Sharp & Dohme LLC$197,706Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc2025
2025-12-31Eli Lilly and Company$105,993Research paymentCash or cash equivalentA PHASE 1A/1B TRIAL OF LY3962673 IN PARTICIPANTS WITH KRAS G12D-MUTANT SOLID TUMORS2025
2025-12-31Merck Sharp & Dohme LLC$94,409Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable 2025
2025-12-31Merck Sharp & Dohme LLC$55,389Research paymentIn-kind items and servicesPADCEV Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-31Balt USA, LLC$37,410Research paymentCash or cash equivalentThe SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)2025
2025-12-31Merck Sharp & Dohme LLC$36,266Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2025
2025-12-31Merck Sharp & Dohme LLC$34,811Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a M2025
2025-12-31Merck Sharp & Dohme LLC$31,128Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i2025
2025-12-31Merck Sharp & Dohme LLC$30,157Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-31JAZZ PHARMACEUTICALS INC.$24,887Research paymentCash or cash equivalentEvaluation of selected test items for anticonvulsant activity in mouse scPTZ (85mg/kg s.c.) model of myoclonic generalis2025
2025-12-31KARL STORZ Endoscopy-America$22,239EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2025
2025-12-31Merck Sharp & Dohme LLC$21,745Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P2025
2025-12-31Merck Sharp & Dohme LLC$17,540Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2025
2025-12-31Merck Sharp & Dohme LLC$16,351Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera2025
2025-12-31Siemens Medical Solutions USA, Inc.$16,057Research paymentIn-kind items and servicesMultitom Rax Device, DI - X-Ray ProductsAssessment of novel 3D imaging features of Multitom Rax2025
2025-12-31JAZZ PHARMACEUTICALS INC.$13,222Research paymentCash or cash equivalentZIIHERA Drug, HEMATOLOGY/ONCOLOGYI-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)2025
2025-12-31Merck Sharp & Dohme LLC$10,300Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792025
2025-12-31Sumitomo Pharma America, Inc.$10,199Research paymentIn-kind items and servicesA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-31PFIZER INC.$9,981Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-31KARL STORZ Endoscopy-America$8,536EducationIn-kind items and servicesIMAGE 1 Device, T-VIDEOIMAGING2025
2025-12-31Merck Sharp & Dohme LLC$7,126Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2025
2025-12-31KARL STORZ Endoscopy-America$6,608EducationIn-kind items and servicesHOPKINS Device, K-LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$6,450EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2025
2025-12-31Merck Sharp & Dohme LLC$6,425Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYPhase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma2025
2025-12-31KARL STORZ Endoscopy-America$5,966EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2025
2025-12-31KARL STORZ Endoscopy-America$5,966EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2025
2025-12-31BioFire Diagnostics, LLC$5,350Research paymentIn-kind items and servicesBIOFIRE SPOTFIRE Module Device, DiagnosticsSpotFire STI Prospective Study2025
2025-12-31BioFire Diagnostics, LLC$5,350Research paymentIn-kind items and servicesBIOFIRE SPOTFIRE Module Device, DiagnosticsSpotFire STI Prospective Study2025
2025-12-31PFIZER INC.$2,938Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA2025
2025-12-31Stryker Corporation$2,739Debt forgivenessCash or cash equivalent2025
2025-12-31ABBVIE INC.$1,656Research paymentIn-kind items and servicesVYALEV Drug, NEUROSCIENCEAn Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure2025
2025-12-31HemoSonics LLC$1,500Research paymentIn-kind items and servicesQUNATRA QPLUS SYSTEM Device, HEMATOLOGYEvaluation of the Clinical Performance of the Quantra System with the QStat Cartridge in Obstetric Patients2025
2025-12-31KARL STORZ Endoscopy-America$1,231EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$1,141EducationIn-kind items and services2025
2025-12-31Abbott Laboratories$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentINFINITY Device, Structural Heart2025
2025-12-31KARL STORZ Endoscopy-America$809EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2025
2025-12-31KARL STORZ Endoscopy-America$681EducationIn-kind items and servicesn.a. Device, D-ENT2025
2025-12-31ABBVIE INC.$600Research paymentIn-kind items and servicesA Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combin2025
2025-12-31KARL STORZ Endoscopy-America$333EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2025
2025-12-31Boehringer Ingelheim Pharmaceuticals, Inc.$313Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYIdiopathic Pulmonary Fibrosis Prospective Outcome Registry2025
2025-12-31ABBVIE INC.$296Research paymentIn-kind items and servicesA First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies2025
2025-12-31Stryker Corporation$161Debt forgivenessCash or cash equivalent2025
2025-12-31Boehringer Ingelheim Pharmaceuticals, Inc.$131Research paymentIn-kind items and servicesOFEV Drug, RESPIRATORYIdiopathic Pulmonary Fibrosis Prospective Outcome Registry2025
2025-12-31Stryker Corporation$130Debt forgivenessCash or cash equivalent2025
2025-12-31KARL STORZ Endoscopy-America$120EducationIn-kind items and services2025
2025-12-31KARL STORZ Endoscopy-America$120EducationIn-kind items and servicesn.a. Device, NEUROSURGERY2025
2025-12-31Teleflex LLC$99Long term medical supply or device loanCash or cash equivalentDEKNATEL Device, SURGICAL2025
2025-12-31Merck Sharp & Dohme LLC$63Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEA Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-2025
2025-12-30PharmaEssentia USA Corporation$11,880Research paymentCash or cash equivalentP1101ET2025
2025-12-30Synthes GmbH$6,000GrantCash or cash equivalent2025
2025-12-30Abbott Laboratories$1,500Research paymentCash or cash equivalentFLEXABILITY Device, Structural HeartNCT05839873--Abbott Ventricular Tachycardia PAS2025
2025-12-29Janssen Research & Development, LLC$119,809Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-12-29Janssen Research & Development, LLC$13,592Research paymentCash or cash equivalentA Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance2025
2025-12-29Medical Device Business Services, Inc.$4,825Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-29Janssen Research & Development, LLC$3,406Research paymentCash or cash equivalentA Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred2025
2025-12-27Medacta USA, Inc.$2,376Research paymentCash or cash equivalentGMK Hinge Device, DevicesMidterm Survival of the Medacta GMK Hinge in Primary and Revision Total Knee Arthroplasty2025
2025-12-26SEAGEN INC.$12,390Research paymentCash or cash equivalentA PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48A2025
2025-12-26PFIZER INC.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-12-26Janssen Research & Development, LLC$1,224Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2025
2025-12-26Janssen Research & Development, LLC$697Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2025
2025-12-25PFIZER INC.$17,365Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2025
2025-12-24United Therapeutics Corporation$6,242Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$4,565Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24Edwards Lifesciences Corporation$3,000Research paymentCash or cash equivalentCLASP IIF (2018-07)2025
2025-12-24PFIZER INC.$2,075Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY 2025
2025-12-24United Therapeutics Corporation$1,952Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24CSL Behring$36Research paymentIn-kind items and servicesHEMGENIX Biological, HematologyAn Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ2025
2025-12-23PharmaEssentia USA Corporation$13,686Research paymentCash or cash equivalentBESREMI Drug, OncologyA22-2032025
2025-12-23ABBVIE INC.$6,265Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-23Scientia Vascular$5,500Research paymentCash or cash equivalentMO-ADAPT2025
2025-12-23BeOne Medicines Ltd.$4,313Research paymentCash or cash equivalentBRUKINSA Drug, OncologyA Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax2025
2025-12-23ABBVIE INC.$1,830Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-23ABBVIE INC.$1,830Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-23ABBVIE INC.$1,830Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-23ABBVIE INC.$467Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-22Janssen Research & Development, LLC$16,361Research paymentCash or cash equivalentA Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic A2025
2025-12-22Janssen Research & Development, LLC$13,310Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi2025
2025-12-22Janssen Research & Development, LLC$7,143Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2025
2025-12-22Janssen Research & Development, LLC$6,370Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyA Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric 2025
2025-12-22SANOFI US SERVICES INC.$5,617Consulting FeeCash or cash equivalent2025
2025-12-22Janssen Research & Development, LLC$4,862Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2025
2025-12-22La Jolla Pharmaceutical Company$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentGIAPREZA Drug, EMERGENT HYPOTENSION2025
2025-12-19Janssen Scientific Affairs, LLC$250,000GrantCash or cash equivalent2025
2025-12-19ADC THERAPEUTICS AMERICA, INC.$24,099Research paymentCash or cash equivalentZYNLONTA Drug, ONCOLOGYIIT_EPPERLA_ADCT-402-12025
2025-12-19Regeneron Pharmaceuticals, Inc.$6,515Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN2025
2025-12-19ADC THERAPEUTICS AMERICA, INC.$4,550Research paymentCash or cash equivalentZYNLONTA Drug, ONCOLOGYIIT_EPPERLA_ADCT-402-12025
2025-12-19Regeneron Pharmaceuticals, Inc.$3,296Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS W2025
2025-12-19ABBVIE INC.$2,666Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$2,666Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$2,472Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$2,472Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$2,472Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19Stryker Corporation$2,113Research paymentCash or cash equivalentTORNIER PERFORM REVERSED AUGMENTED GLENOID Device, BONE SUBSTITUTEPERFORM HUMERAL SYSTEM STUDY (PHS)2025
2025-12-19ABBVIE INC.$1,725Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$1,620Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$1,620Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$1,620Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19PFIZER INC.$1,400Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY 2025
2025-12-19ABBVIE INC.$675Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$675Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$675Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$554Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$554Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$554Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ADC THERAPEUTICS AMERICA, INC.$500Research paymentCash or cash equivalentZYNLONTA Drug, ONCOLOGYIIT_EPPERLA_ADCT-402-12025
2025-12-19ABBVIE INC.$387Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-19ABBVIE INC.$387Research paymentCash or cash equivalentStudy to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (2025
2025-12-18Janssen Scientific Affairs, LLC$68,850Research paymentCash or cash equivalentDARZALEX Biological, OncologyLongitudinal Multi-Center Chart Review Data Repository For Multiple Myeloma2025
2025-12-18Alcon Research LLC$29,625Research paymentCash or cash equivalentHYDRUS Microstent Device, Ophthalmology3 Year Outcomes of Combined Hydrus Microstent with iTrack Canaloplasty2025
2025-12-18Glaukos Corporation$18,900Research paymentCash or cash equivalentPRESERFLO MicroShunt Device, OphthalmologyProspective, Multicenter Study of PRESERFLOMicroShunt in Subjects with Primary Open-AngleGlaucoma Who Have Failed Previo2025
2025-12-18Genentech, Inc.$13,852Research paymentCash or cash equivalentActemra Biological, ImmunologyPhase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients2025
2025-12-18SANOFI US SERVICES INC.$10,785Research paymentCash or cash equivalentAYVAKIT Biological, GastroenterologyA 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU2025
2025-12-18Boston Scientific Corporation$10,000GrantCash or cash equivalentGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-18SANOFI US SERVICES INC.$1,905Research paymentCash or cash equivalentAYVAKIT Biological, GastroenterologyA 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU2025
2025-12-18Janssen Research & Development, LLC$1,525Research paymentCash or cash equivalentA Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred2025
2025-12-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18Becton, Dickinson and Company$120Charitable ContributionCash or cash equivalent2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-17Ionis Pharmaceuticals, Inc.$71,528Research paymentCash or cash equivalentTRYNGOLZA Drug, CARDIOLOGYOlezarsen for treatment of Familial Chylomicromenia syndrome2025
2025-12-17Boehringer Ingelheim Pharmaceuticals, Inc.$25,120Research paymentCash or cash equivalentBeamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere2025
2025-12-17PFIZER INC.$24,451Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY 2025
2025-12-17Synthes GmbH$22,500GrantCash or cash equivalent2025
2025-12-17Sumitomo Pharma America, Inc.$16,321Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17Sumitomo Pharma America, Inc.$13,596Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17Sumitomo Pharma America, Inc.$13,596Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17Sumitomo Pharma America, Inc.$13,345Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-17Sumitomo Pharma America, Inc.$11,486Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-17Sumitomo Pharma America, Inc.$8,000Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-17Synthes GmbH$7,500GrantCash or cash equivalent2025
2025-12-17Sumitomo Pharma America, Inc.$7,006Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17PFIZER INC.$3,421Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-17Takeda Pharmaceuticals U.S.A., Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-17Takeda Pharmaceuticals U.S.A., Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-17Daiichi Sankyo Inc.$2,685Research paymentCash or cash equivalentDS3939-0772025
2025-12-17Daiichi Sankyo Inc.$1,184Research paymentCash or cash equivalentDS3939-0772025
2025-12-17Medtronic, Inc.$921Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2025
2025-12-17Sumitomo Pharma America, Inc.$280Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17Sumitomo Pharma America, Inc.$120Research paymentCash or cash equivalentA PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS2025
2025-12-17Abbott Laboratories$99Research paymentCash or cash equivalentI-STAT Device, Point of CareISM2404009A--Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury2025
2025-12-16Boston Scientific Corporation$48,354Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_NMDIMPROVE2025
2025-12-16Incyte Corporation$18,721Research paymentCash or cash equivalentA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita2025
2025-12-16BeOne Medicines USA, Inc.$6,370Research paymentCash or cash equivalentBRUKINSA Drug, OncologyA Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients W2025
2025-12-16PFIZER INC.$6,112Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA2025
2025-12-16PFIZER INC.$5,890Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY 2025
2025-12-16PFIZER INC.$5,696Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2025
2025-12-16Janssen Research & Development, LLC$1,901Research paymentCash or cash equivalentA Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial C2025
2025-12-16PTC Therapeutics, Inc.$117Research paymentCash or cash equivalentA PHASE 3 OPEN-LABEL STUDY OF PTC923 (SEPIAPTERIN) IN PHENYLKETONURIA2025
2025-12-15Merck Sharp & Dohme LLC$299,879Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYPhase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma2025
2025-12-15Merck Sharp & Dohme LLC$257,224Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-15Merck Sharp & Dohme LLC$161,327Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2025
2025-12-15Boehringer Ingelheim Pharmaceuticals, Inc.$13,410Research paymentCash or cash equivalentBeamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere2025
2025-12-15Edwards Lifesciences Corporation$12,630Research paymentCash or cash equivalentCOMPASSION S3 2015-012025
2025-12-15Janssen Research & Development, LLC$7,915Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi2025
2025-12-15Janssen Research & Development, LLC$6,108Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyA Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric 2025
2025-12-15Novo Nordisk Inc$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentWegovy Drug, Obesity2025
2025-12-15Boehringer Ingelheim Pharmaceuticals, Inc.$4,371Research paymentCash or cash equivalentBeamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administere2025
2025-12-15Janssen Research & Development, LLC$1,926Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2025
2025-12-15Janssen Research & Development, LLC$561Research paymentCash or cash equivalentLong-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (A2025
2025-12-12Janssen Research & Development, LLC$4,300Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2025
2025-12-12Janssen Research & Development, LLC$1,750Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2025
2025-12-11Sumitomo Pharma America, Inc.$255,865Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-11Incyte Corporation$26,447Research paymentCash or cash equivalentA Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United St2025
2025-12-11Regeneron Pharmaceuticals, Inc.$14,645Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN2025
2025-12-11Incyte Corporation$10,579Research paymentCash or cash equivalentA Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United St2025
2025-12-11BeOne Medicines Ltd.$2,672Research paymentIn-kind items and servicesA Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy,2025
2025-12-11Ipsen Pharma SAS$2,516Research paymentCash or cash equivalentDysport Drug, NeurologyA Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Deve2025
2025-12-11Edwards Lifesciences Corporation$2,180Research paymentCash or cash equivalentALTERRA Post-Approval Study 2021-112025
2025-12-11Ferring Pharmaceuticals AS$2,150Research paymentCash or cash equivalentADSTILADRIN Biological, ONCOLOGYADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States2025
2025-12-11Syndax Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYEXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCI2025
2025-12-11Ferring Pharmaceuticals AS$1,000Research paymentCash or cash equivalentADSTILADRIN Biological, ONCOLOGYADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States2025
2025-12-11Sumitomo Pharma America, Inc.$0Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Oth2025
2025-12-10Boston Scientific Corporation$362,323GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-10Alexion Pharmaceuticals, Inc.$24,925Research paymentCash or cash equivalentSTRENSIQ Biological, Rare DiseaseA Prospective Observational Sub Study of the Global Hypophosphatasia Registry to Evaluate the Potential Risk of Immune M2025
2025-12-10ABBVIE INC.$18,241Research paymentCash or cash equivalentA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-12-10Merck Sharp & Dohme LLC$8,133Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i2025
2025-12-10Eidos Therapeutics, Inc.$3,240Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P2025
2025-12-10Abbott Laboratories$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentINFINITY Device, Structural Heart2025
2025-12-10Eidos Therapeutics, Inc.$2,500Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P2025
2025-12-10Draeger Medical Systems, Inc$1,500EducationCash or cash equivalentEvita V800 Device, Pulmonary/Respiratory Diseases2025
2025-12-10Takeda Pharmaceuticals U.S.A., Inc.$395Research paymentCash or cash equivalentA PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL2025
2025-12-10Eidos Therapeutics, Inc.$270Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P2025
2025-12-09BeOne Medicines Ltd.$282,156Research paymentCash or cash equivalentBRUKINSA Drug, OncologyA Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax2025
2025-12-09BeOne Medicines USA, Inc.$57,175Research paymentCash or cash equivalentBRUKINSA Drug, OncologyA Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients W2025
2025-12-09Merck Sharp & Dohme LLC$34,843Research paymentCash or cash equivalentENFLONSIA Drug, INFECTIOUS DISEASEThe Use of Antibiotics for RSV in Hospitalized Children <2 Years of Age2025
2025-12-09Medtronic, Inc.$9,000Research paymentCash or cash equivalentPISCES-QUAD PLUS Device, Spinal Cord NeurostimulationPSR-PSTM2025
2025-12-09ABBVIE INC.$3,975Research paymentCash or cash equivalentA First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies2025
2025-12-08ACADIA Pharmaceuticals Inc$21,938Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-12-08Visby Medical, Inc.$10,000Royalty or LicenseCash or cash equivalentVisby Medical Sexual Health Click Test Device, Sexual Health Test2025
2025-12-08ABBVIE INC.$7,792Research paymentCash or cash equivalentPhase 1b Study to Investigate ABBV-CLS-7262s Safety Tolerability & Pharmacokinetics in Vanishing White Matter Patients2025
2025-12-08GENZYME CORPORATION$2,814Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropath2025
2025-12-08Liquidia Technologies, Inc.$2,000Research paymentCash or cash equivalentYUTREPIA Drug, PulmonaryA Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil2025
2025-12-08Liquidia Technologies, Inc.$2,000Research paymentCash or cash equivalentYUTREPIA Drug, PulmonaryA Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil2025
2025-12-08Liquidia Technologies, Inc.$1,836Research paymentCash or cash equivalentYUTREPIA Drug, PulmonaryA Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil2025
2025-12-08Liquidia Technologies, Inc.$1,836Research paymentCash or cash equivalentYUTREPIA Drug, PulmonaryA Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil2025

The latest 200 records of 3,756.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Salt Lake CountySalt Lake City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.

MeasurePlace (city or town)
Salt Lake City, UT
County
Salt Lake County, UT
State
Utah
Population B01003208,0071,196,5233,392,331
Population, 2020 census P1199,7231,185,2383,271,616
Median age B0100232.934.032.0
Under 18 B0100116.4%25.3%27.8%
65 and over B0100112.5%11.9%11.9%
Households B1100192,652426,2451,124,822
Foreign born B0500214.9%13.5%8.9%
Median household income B19013$75,090$97,494$95,166
Median family income B19113$109,291$116,682$109,675
Per capita income B19301$51,173$45,106$40,873
Poverty rate B1700113.6%8.1%8.5%
Unemployment rate B230254.2%3.8%3.6%
Civilian labor force B23025129,830670,9001,778,106
Mean commute (minutes) B0801319.522.322.1
Bachelor's degree or higher B1500351.5%39.4%37.7%
Housing units B25001101,188449,6621,223,468
Owner-occupied B2500345.8%66.1%70.2%
Renters B2500354.2%33.9%29.8%
Median home value B25077$539,500$525,700$489,400
Median gross rent B25064$1,414$1,592$1,496
White, not Hispanic B0300264.4%66.6%74.7%
Black B030022.3%1.7%1.1%
Hispanic or Latino B0300220.8%20.6%15.9%
Asian B030024.9%4.2%2.4%
American Indian and Alaska Native B030020.5%0.5%0.6%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.